BeyondSpring, which is developing a therapy for chemotherapy-induced neutropenia, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The New York, NY-based company was founded in 2014 and plans to list on the Nasdaq under the symbol BYSI. Citi, Guggenheim Securities, FBR Capital Markets and China Renaissance are the joint bookrunners on the deal. No pricing terms were disclosed.
